Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with MTAP -Deleted Cancers
Journal of Medicinal Chemistry · 25.04.2024 · 67 (8) · 6064-6080
DOI: 10.1021/acs.jmedchem.4c00133 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 10.04.2024. Verfasst von Kevin M Cottrell und 17 weiteren Autor:innen. Beteiligte Einrichtung: Tango Therapeutics, Boston, Massachusetts 02215, United States. Hauptthemen laut MEDLINE: Protein-Arginine N-Methyltransferases, Antineoplastic Agents. Die Arbeit wurde bisher 85-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tango Therapeutics.
Abstract (Originalsprache)
It has been shown that PRMT5 inhibition by small molecules can selectively kill cancer cells with homozygous deletion of the MTAP gene if the inhibitors can leverage the consequence of MTAP deletion, namely, accumulation of the MTAP substrate MTA. Herein, we describe the discovery of TNG908, a potent inhibitor that binds the PRMT5·MTA complex, leading to 15-fold-selective killing of MTAP-deleted (MTAP-null) cells compared to MTAPintact (MTAP WT) cells. TNG908 shows selective antitumor activity when dosed orally in mouse xenograft models, and its physicochemical properties are amenable for crossing the blood-brain barrier (BBB), supporting clinical study for the treatment of both CNS and non-CNS tumors with MTAP loss.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Tango Therapeutics, Boston, Massachusetts 02215, United States.
ORCID-Profile: Kevin M Cottrell, Douglas A Whittington, John P Maxwell
Förderung
- Tango Therapeutics
Zitieren
APA
Cottrell, K. M., Briggs, K. J., Whittington, D. A., Jahic, H., Ali, J. A., Davis, C. B., Gong, S., Gotur, D., Gu, L., McCarren, P., Tonini, M. R., Tsai, A., Wilker, E. W., Yuan, H., Zhang, M., Zhang, W., Huang, A., & Maxwell, J. P. (2024). Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with MTAP -Deleted Cancers. Journal of Medicinal Chemistry, 67(8), 6064-6080. https://doi.org/10.1021/acs.jmedchem.4c00133
Vancouver
Cottrell KM, Briggs KJ, Whittington DA, Jahic H, Ali JA, Davis CB, et al. Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with MTAP -Deleted Cancers. Journal of Medicinal Chemistry. 2024;67(8):6064-6080. doi:10.1021/acs.jmedchem.4c00133
BibTeX
@article{Cottrell2024,
author = {Cottrell, Kevin M and Briggs, Kimberly J and Whittington, Douglas A and Jahic, Haris and Ali, Janid A and Davis, Charles B and Gong, Shanzhong and Gotur, Deepali and Gu, Lina and McCarren, Patrick and Tonini, Matthew R and Tsai, Alice and Wilker, Erik W and Yuan, Hongling and Zhang, Minjie and Zhang, Wenhai and Huang, Alan and Maxwell, John P},
title = {Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with MTAP -Deleted Cancers},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {8},
pages = {6064--6080},
doi = {10.1021/acs.jmedchem.4c00133}
}
EUVIMED